Fig. 1
From: Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies
Identification of ganciclovir (GCV)-associated mutational signature from targeted sequencing cancer cohorts. A Trinucleotide mutational spectrum from an in-house colorectal cancer patient with GCVsig. B Identification of samples with GCVsig from patients from AACR Project GENIE and Foundation Medicine cohorts. One percent FDR is set at the sigfit GCVsig contribution score at which there is a 1% chance that the observed mutational spectrum arose from SBS18 (green line) or SBS38 (blue line). Samples with mutation contribution from GCV only or multiple mutational processes are also indicated. C Sample spectrum from one example patient from the AACR Project GENIE cohort with GCVsig. The mutational spectra of the other 21 GENIE + FM samples with GCVsig are shown in Additional file 3: Fig. S2. D Oncoprint of recurrent mutations in CA > AA context across 22 patients with GCVsig. Mutations from KRAS, HRAS, and NRAS were combined and labelled as RAS. Cancer type abbreviations: bladder cancers (BLCA), gastrointestinal epithelial cancers (GI), haematolymphoid malignancies (HEME), head and neck cancers (HNSC), sarcoma (SARC), skin cancers (SKIN), and other/unknown primary cancers (OTHER). E Mutational potential of known hotspot driver mutations from COSMIC cancer census genes, based on the ability of GCVsig to access trimer sequences (listed in descending order of accessibility)